FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II clinical studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||6 mg/mL in DMSO|
Comparing FK-506 with basic fibroblast growth factor (b-FGF) on the repair of a peripheral nerve defect using an autogenous vein bridge model.
Chaiyasate K, et al. J Invest Surg. 2009 Nov-Dec;22(6):401-5. PMID: 20001808.
Wnt/beta-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression.
Aman A, et al. Dev Cell. 2008 Nov;15(5):749-61. PMID: 19000839.
|Related FGFR Products|
FIIN-3 is a potent, selective, irreversible and the next-generation covalent FGFR inhibitor with IC50 values of 13.1, 21, 31.4 and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.
FGFR4-IN-1 is a potent and selective FGFR4 inhibitor with IC50 of 0.7 nM.
PD-166866 is a synthetic molecule inhibiting the tyrosin kinase action of FGFR1, shows a very high selectivity towards FGFR1 and inhibits the auto-phosphorylation activity of FGRF1.
BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.